MedTrace Logo

Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension

NCT00765947 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 256

Last updated 2020-08-06

Study results available
· View outcomes & findings →

Summary

This study will assess the efficacy of an aliskiren based treatment regimen in reaching blood pressure (BP) target in patients with mild to moderate hypertension. (defined as mean sitting Systolic Blood Pressure \[msSBP\] ≥ 140 mmHg and \< 180 mmHg and/or mean sitting Diastolic Blood Pressure \[msDBP\] ≥ 90 and \<110 mmHg).

Conditions

  • Essential Hypertension ( Mild to Moderate)

Interventions

DRUG

Aliskiren

Aliskiren 150 or 300 mg

DRUG

Hydrochlorothiazide

Hydrochlorothiazide 12.5 or 25 mg

DRUG

Amlodipine

Amlodipine 5 or 10 mg

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • France
  • Hungary
  • Romania
  • Slovakia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00765947 on ClinicalTrials.gov